Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer
Titel:
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer
Auteur:
Pivot, Xavier Pegram, Mark Cortes, Javier Lüftner, Diana Lyman, Gary H. Curigliano, Giuseppe Bondarenko, Igor Yoon, Ye Chan Kim, Younsoo Kim, Chul